AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device

MOUNTAIN VIEW, Calif., Jan. 11, 2011 /PRNewswire/ -- AccessClosure, Inc., the U.S. market leader in extravascular closure devices, announced today the launch of its next generation product, the Mynx Cadence Vascular Closure Device (VCD).  With its simpler design and improved ease-of-use, Mynx Cadence offers physicians smoother device deployment while maintaining all the benefits of the original Mynx.

(Logo:  http://photos.prnewswire.com/prnh/20110111/SF27857LOGO)

"We are extremely excited about the launch of the Mynx Cadence," said Gregory D. Casciaro, President and CEO of AccessClosure.   "Designing enhanced solutions for vascular closure is our top priority and the design changes incorporated into the Mynx Cadence make it easier to use while maintaining the same feel our users have grown accustomed to.  We believe this device provides an excellent platform for growth as we continue to expand our user base."

Three design changes on the new Mynx Cadence device make it easier and more consistent to deploy.  A definitive shuttle stop when deploying the sealant reduces the possibility of over-shuttling.  Additionally, a single marker on the advancer tube removes any guesswork around sealant compression.  Finally, a new sealant sleeve protects the sealant during deployment and shortens the procedure time by eliminating the need to pre-soak during device preparation.  These changes result in more consistent sealant delivery every time.  

"My initial experience with the Mynx Cadence has been very positive," said Elias Kassab, MD, FACC, an Interventional Cardiologist from Oakwood Hospital in Detroit, Michigan.  "The design changes inspire increased confidence in the device, but I don't feel that I've lost any of the tactile feedback I'm used to with the Mynx.  These changes truly improve the experience of deploying the Mynx."

The Mynx Vascular Closure Device utilizes a conformable, water-soluble polyethylene glycol (PEG) sealant to seal the femoral artery, which dissolves within 30 days, leaving nothing behind but a healed artery. The Mynx received its first FDA approval in May 2007, has been used in over 700,000 procedures, and is available in two sizes for 5F and 6F/7F procedural sheaths.  

AccessClosure will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, in San Francisco. Gregory D. Casciaro, President and CEO, will address the conference at 4:00 p.m. PST.

About Vascular Closure

There are two methods of closing the femoral artery after cardiovascular procedures – manual compression and vascular closure devices.  Manual compression entails up to 30 minutes of firm manual pressure applied directly to the access site, which is often painful for the patient, followed by many hours of bed rest in a hospital recovery room.  Physicians frequently choose to use a vascular closure device (VCD) as an alternative to manual compression because it stops the bleeding more quickly, thereby allowing patients to leave the hospital earlier.

However, despite the benefits of VCDs, many patients find that deployment of a VCD is extremely painful.  The Mynx addresses this shortcoming by eliminating the tugging and cinching of the artery that occurs with other closure devices.  The sealant is designed for gentle placement on top of the artery without the use of a suture or permanent metal implant.  

About AccessClosure

Founded in 2002, AccessClosure, Inc. is a privately held medical device company pioneering innovative access site management products designed to provide a reliable, patient-friendly vascular closure experience.  For more information, visit our website at www.accessclosure.com.

SOURCE AccessClosure, Inc.